Why you're losing muscle on Ozempic (and what to do about it)

The number your doctor gives you is the wrong number

You step on the scale at your prescriber’s office. Down fourteen pounds in two months. Everyone is pleased. The number in your chart drops, and the visit ends with a refill and a follow-up in eight weeks.

But that number — the one that insurance companies track, that clinical trials report as the primary endpoint, that your prescriber uses to gauge whether semaglutide or tirzepatide is “working” — is hiding something important. It tells you how much less you weigh. It tells you nothing about what you lost.

When researchers in the STEP 1 trial put participants through dual-energy X-ray absorptiometry (DXA) scans rather than just weighing them, the picture changed. Of the weight lost on semaglutide 2.4 mg, roughly 39% was lean mass (Wilkinson et al., 2024, The Lancet Diabetes & Endocrinology). The SURMOUNT trials for tirzepatide showed similar proportions — somewhere between 33% and 40% of total weight lost came from muscle, bone mineral density, and other non-fat tissue (Jastreboff et al., 2022, NEJM). This is not a rounding error. If you’ve lost thirty pounds, ten to twelve of those pounds may have been muscle.

Why don’t prescribers address this? Several reasons, none of them conspiratorial. The reimbursement model rewards weight reduction, full stop. Office visits run fifteen minutes, and body composition counseling takes longer than that. There are no consensus guidelines from endocrinology societies on muscle preservation during GLP-1 therapy — the guidelines haven’t caught up to the prescribing volume. And frankly, many prescribers are internists or family medicine physicians who weren’t trained in exercise physiology or sports nutrition. They know the drug works for weight. The composition of that weight loss isn’t on their radar yet.

If you’ve been on a GLP-1 agonist for a few months and something feels off — you’re lighter but weaker, your arms look smaller, you’re winded going up stairs in a way that doesn’t match being “healthier” — you’re not imagining it. The scale improved. Your body composition may not have.

Why this happens: the physiology of GLP-1-induced muscle loss

Let’s be specific about the mechanism, because understanding it changes how you intervene.

At the most fundamental level, your body maintains muscle through a constant balance between muscle protein synthesis (MPS) and muscle protein breakdown (MPB). When synthesis exceeds breakdown, you build or maintain muscle. When breakdown exceeds synthesis, you lose it. This balance is called net protein balance, and it’s exquisitely sensitive to energy availability.

During caloric restriction — any caloric restriction — the body enters a state of negative nitrogen balance. You are not taking in enough amino acids to fully support the rate at which your tissues turn over. The body responds by upregulating proteolytic pathways, primarily the ubiquitin-proteasome system, which tags muscle proteins for degradation and recycles the amino acids for more critical functions: immune response, organ maintenance, gluconeogenesis (Carbone et al., 2012, International Journal of Sport Nutrition and Exercise Metabolism). Muscle is metabolically expensive tissue, and when energy is scarce, the body treats it as a reserve fuel tank.

This happens during any diet. What makes GLP-1 receptor agonists different is the depth and completeness of appetite suppression. Most diets fail because hunger eventually overwhelms willpower. GLP-1s bypass that entirely. Semaglutide acts on GLP-1 receptors in the hypothalamus, the nucleus tractus solitarius, and the area postrema, fundamentally altering satiety signaling (Turton et al., 1996, Nature). Many patients report not just reduced hunger but genuine food indifference — a phenomenon that doesn’t occur with caloric restriction alone. The result is that GLP-1 users often sustain deficits of 500 to 1,000 calories per day without effort, and sometimes much more.

Here is where the muscle loss accelerates. When appetite collapses, protein intake collapses with it. A patient who previously ate 2,000 calories and 90 grams of protein per day might now eat 1,200 calories and 45 grams of protein. That 45 grams, spread across two or three small meals, means each meal contains maybe 15 to 20 grams of protein. This is below the leucine threshold.

Leucine — one of the three branched-chain amino acids — is the primary signal that activates the mTORC1 pathway, which is the molecular switch for muscle protein synthesis. The threshold is approximately 2.5 to 3 grams of leucine per meal (Norton & Layman, 2006, Journal of Nutrition). Below that threshold, mTORC1 activation is minimal. You can eat protein, but if the leucine content of that meal doesn’t hit the threshold, you don’t get meaningful MPS stimulation. A meal with 15 grams of mixed-quality protein contains roughly 1.2 to 1.5 grams of leucine. That’s half of what you need. You’re eating, but you’re not sending the build signal to your muscles.

Meanwhile, the catabolic side is ramping up. Aggressive caloric restriction upregulates myostatin, a negative regulator of muscle growth that acts as a brake on the Akt/mTOR pathway (Reza et al., 2017, Cellular Signalling). The growth hormone/IGF-1 axis, which normally supports muscle maintenance, becomes dysregulated during rapid weight loss — GH levels may actually rise (a starvation response), but hepatic IGF-1 production drops because IGF-1 synthesis requires adequate energy and amino acid availability (Clemmons, 2004, Molecular and Cellular Endocrinology). So you have elevated GH with low IGF-1, which is the hormonal signature of catabolism, not anabolism.

The speed makes it worse. A person dieting without medication might lose one to two pounds per week. GLP-1 users frequently lose three to five pounds per week in the first few months. The rate of muscle loss scales with the severity of the caloric deficit (Heymsfield et al., 2014, American Journal of Clinical Nutrition). A 500-calorie daily deficit produces a different lean mass:fat mass loss ratio than a 1,000-calorie deficit. The more aggressive the restriction, the higher the proportion of weight lost from muscle. GLP-1s, by making extreme restriction effortless, push patients into deficit severities that would have been unsustainable — and therefore self-limiting — with willpower alone.

This isn’t a flaw in the drug. It’s a predictable consequence of the physiology. The drug does what it’s designed to do. The muscle loss is what happens when nobody addresses the downstream effects.

Why this matters more than you think

There’s a temptation to dismiss muscle loss during GLP-1 therapy as an acceptable cost of becoming lighter. After all, the metabolic benefits of losing excess adipose tissue are real — improved insulin sensitivity, reduced inflammatory markers, lower cardiovascular risk. These are not trivial. But the muscle loss creates a separate set of problems that compound over time, and they’re worth understanding clearly.

Each pound of skeletal muscle burns approximately 6 calories per day at rest (Wang et al., 2010, American Journal of Clinical Nutrition). That doesn’t sound like much until you do the arithmetic over a meaningful amount of lean mass loss. If you lose twenty pounds of muscle during a year on semaglutide — which is possible if you started at a high body weight and lost aggressively without intervention — your resting metabolic rate has dropped by roughly 120 calories per day. That’s 840 calories per week. Over a year, that’s the caloric equivalent of about 12.5 pounds of fat. You’ve created a metabolic environment where maintaining your new weight requires eating substantially less than someone at the same weight who didn’t lose that muscle. This is one of the key mechanisms behind the weight regain that occurs when patients discontinue GLP-1 therapy.

The STEP 4 extension trial documented this vividly. Patients who discontinued semaglutide regained approximately two-thirds of their lost weight within a year (Rubino et al., 2021, JAMA). But the composition of the regain was not symmetrical to the loss. Fat mass rebounds faster than lean mass because adipogenesis (fat cell filling) is metabolically cheap, while myogenesis (muscle rebuilding) requires mechanical stimulus, adequate protein, and time. You lose muscle and fat roughly together on the way down. On the way back up, you gain mostly fat. The net result is a worse body composition than before you started — the same weight, but more fat and less muscle. This is the rebound composition problem, and it’s documented across multiple weight cycling studies (Dulloo et al., 2015, International Journal of Obesity).

For older adults — and a growing proportion of GLP-1 prescriptions are going to patients over 60 — the muscle loss carries immediate functional consequences. Sarcopenia, the age-related loss of muscle mass and strength, is already progressing in this population. Layering aggressive GLP-1-induced muscle loss on top of age-related sarcopenia accelerates the decline in functional capacity: difficulty rising from chairs, reduced grip strength, increased fall risk (Cruz-Jentoft et al., 2019, Age and Ageing). A 65-year-old who loses fifteen pounds of muscle doesn’t just have a slower metabolism. They may lose the ability to live independently.

None of this means you shouldn’t take a GLP-1 if it’s indicated. The cardiovascular and metabolic benefits of losing excess fat are real and often substantial. But treating muscle loss as a non-issue — or worse, pretending it doesn’t exist because the scale looks good — is a failure of clinical framing. This is a manageable problem. You just have to actually manage it.

The intervention evidence: what actually works

The good news is that the evidence base for preserving lean mass during caloric restriction is strong, well-replicated, and largely applicable to GLP-1 therapy specifically. The interventions fall into a clear hierarchy: resistance training first, protein optimization second, and targeted supplementation third. None of these are exotic. They’re just underutilized because the prescribing pipeline for GLP-1s doesn’t include them.

Resistance training is the non-negotiable

If you do only one thing from this article, this is it. Nothing else — not protein, not creatine, not any supplement — can replace the muscle-preserving signal that resistance training provides during a caloric deficit.

The data is unambiguous. A landmark study by Longland et al. (2016) published in the American Journal of Clinical Nutrition put young men on an aggressive 40% caloric deficit — roughly comparable to what many GLP-1 users experience — and randomized them to resistance training plus high protein versus resistance training plus moderate protein. Both groups preserved lean mass. A control group on the same deficit without resistance training lost significant muscle. The mechanical loading of resistance exercise directly stimulates MPS through mechanotransduction pathways that are partially independent of nutritional status (Hornberger, 2011, International Journal of Biochemistry & Cell Biology). In simpler terms: when you load a muscle against resistance, the muscle receives a signal to maintain itself even when the rest of the body is breaking tissue down for energy.

The meta-analytic evidence confirms this across dozens of trials. Cava et al. (2017) published a systematic review in Obesity Reviews examining body composition outcomes during caloric restriction with and without exercise. The conclusion was consistent: resistance training during energy deficit preserves lean mass. Aerobic exercise alone does not. This distinction matters. Walking, cycling, and swimming are valuable for cardiovascular health, but they do not provide sufficient mechanical stimulus to trigger the mTOR-mediated muscle preservation response. If your only exercise during GLP-1 therapy is cardio, you are not protecting your muscle.

How much resistance training is enough? Less than you think, and this is important because GLP-1 users are often fatigued from low caloric intake and may feel overwhelmed by the idea of a gym program. The minimum effective dose appears to be two sessions per week, focusing on compound movements — exercises that work multiple joints and large muscle groups simultaneously (Schoenfeld et al., 2016, Journal of Sports Sciences). Squats, deadlifts, rows, presses, and lunges. You do not need isolation exercises for biceps and calves. You need to load your major muscle groups through a full range of motion, twice a week, with progressive overload.

Progressive overload is the critical variable, and it’s where many people go wrong. Progressive overload means the stimulus increases over time — more weight on the bar, more reps at the same weight, or more sets. Simply moving through the motions with the same light dumbbells for months is not resistance training in any physiologically meaningful sense. The muscle needs to encounter a load that challenges it beyond its current capacity. That’s the signal. Without progressive overload, you’re doing physical therapy maintenance, not muscle preservation training.

If you haven’t resistance trained before, start conservatively. Bodyweight squats, wall push-ups, dumbbell rows with light weight. But start. And plan to add weight or difficulty every one to two weeks. The adaptation curve for beginners is steep — you’ll be able to handle meaningfully more load within a month, and that’s exactly the signal your muscles need during this caloric deficit.

Protein targets: why the standard recommendation is wrong for you

The Recommended Dietary Allowance (RDA) for protein is 0.8 grams per kilogram of body weight per day. This is the amount required to prevent clinical protein deficiency in a sedentary person at energy balance. It is not — and was never intended to be — the optimal amount for someone in a significant caloric deficit who is trying to preserve muscle mass. The distinction matters, and it’s one that many prescribers miss.

During caloric restriction, protein requirements increase substantially. The body’s demand for amino acids rises because some of those amino acids are being diverted to gluconeogenesis (making glucose from non-carbohydrate sources) and because the increased proteolysis means more amino acids are needed to maintain net protein balance. Morton et al. (2018) published a meta-analysis in the British Journal of Sports Medicine examining protein intake and lean mass changes during resistance training. The dose-response curve plateaued at approximately 1.6 grams per kilogram per day for individuals at energy balance. During caloric deficit, the requirement shifts upward — most researchers in the field now recommend 1.6 to 2.2 grams per kilogram per day for active individuals in a deficit (Phillips & Van Loon, 2011, Journal of Sports Sciences).

Let’s make this concrete. If you weigh 200 pounds (91 kg), the RDA says you need 73 grams of protein per day. The evidence-based target during your GLP-1-induced caloric deficit is 145 to 200 grams per day. That’s roughly double to triple the standard recommendation. And here’s the problem: you’re not hungry. Your GLP-1 medication has made eating feel like a chore. Many patients on semaglutide report eating 1,000 to 1,400 calories per day. Getting 160 grams of protein into 1,200 calories requires that 53% of your total caloric intake come from protein. That doesn’t happen by accident. It requires deliberate planning.

The distribution of that protein across meals matters as much as the total. This is the leucine threshold concept, and it’s one of the most actionable pieces of nutritional science for GLP-1 users. The mTORC1 pathway — the master switch for muscle protein synthesis — is activated by leucine through a specific molecular mechanism: leucine binds to Sestrin2, which releases its inhibition on the GATOR2 complex, which in turn activates mTORC1 via the Rag GTPases (Wolfson et al., 2016, Science). This pathway has a threshold, not a dose-response. You need approximately 2.5 to 3 grams of leucine in a single meal to activate MPS. Below that, activation is minimal. Above it, you don’t get proportionally more stimulation — 6 grams of leucine doesn’t activate mTOR twice as much as 3 grams.

The practical implication: three meals per day, each containing at least 30 to 40 grams of high-quality protein (which provides approximately 2.5 to 3 grams of leucine), triggers MPS three times. Two meals with 20 grams of protein each, even if total daily protein is the same, triggers MPS zero times because neither meal hits the leucine threshold. Distribution is not optional.

Now do the math for a typical GLP-1 user. You eat a 200-calorie breakfast because that’s all you can stomach. A yogurt cup. Maybe 8 grams of protein, roughly 0.7 grams of leucine. No MPS activation. Lunch is half a sandwich — 15 grams of protein, about 1.2 grams of leucine. No MPS activation. Dinner is a small portion of chicken with vegetables — 30 grams of protein, about 2.6 grams of leucine. One MPS activation event in a 24-hour period. Meanwhile, muscle protein breakdown has been running continuously all day. You’re in the red by a wide margin.

This is why protein tracking during the first month of GLP-1 therapy is worth the inconvenience. Not forever — just long enough to learn which meals hit the threshold and which don’t. A protein shake with 30 grams of whey protein is a reliable way to hit the leucine threshold even when appetite is low, because it’s liquid calories that don’t require chewing through food you don’t want.

One more thing on protein sources: collagen protein is a mistake during GLP-1 therapy. Collagen is aggressively marketed as a protein supplement, but it has an amino acid profile that is almost entirely glycine, proline, and hydroxyproline. It contains virtually no leucine — roughly 0.3 grams per 20-gram serving compared to 2.5 grams in whey (Phillips et al., 2009, Journal of the American Dietetic Association). Collagen does not stimulate MPS. If your protein supplement of choice is a collagen powder in your morning coffee, you are getting protein on paper but not the amino acids your muscles need. Switch to whey, casein, or a leucine-rich plant blend (pea protein is reasonable; rice protein combined with pea is better).

Creatine monohydrate: the most underrated tool you’re not using

Creatine is the most extensively studied sports supplement in history, with a safety and efficacy profile that would make most pharmaceutical companies envious. And yet it remains underutilized by the exact population that would benefit most from it: people in a caloric deficit trying to preserve muscle.

The mechanism is straightforward. Your muscles use adenosine triphosphate (ATP) for contraction. During high-intensity efforts — the kind that matter for resistance training — ATP is consumed rapidly. Phosphocreatine donates a phosphate group to regenerate ATP from ADP, allowing you to sustain effort for a few more seconds per set. Creatine supplementation increases intramuscular phosphocreatine stores by 20-40% (Harris et al., 1992, Clinical Science). More phosphocreatine means more ATP regeneration, which means you can do one or two more reps per set at a given weight, or use slightly more weight for the same number of reps. Over weeks of training, that incremental increase in mechanical work translates to a meaningfully greater stimulus for muscle retention.

But creatine’s benefits extend beyond just training performance. There is direct evidence that creatine supplementation during caloric restriction preserves lean mass independently of its performance effects. Devries and Phillips (2014) published a meta-analysis in Medicine & Science in Sports & Exercise examining creatine supplementation during resistance training. The creatine groups gained an average of 1.37 kg more lean mass than placebo groups. In a caloric deficit context, where the goal is preservation rather than growth, this translates to less muscle lost — which is exactly what you need during GLP-1 therapy.

The dose is simple: 3 to 5 grams of creatine monohydrate per day. Every day, regardless of whether you train that day. Timing doesn’t matter meaningfully — take it whenever you’ll remember. Loading protocols (20 grams per day for a week) are optional; they saturate your stores faster, but daily low-dose supplementation reaches the same saturation point within three to four weeks. Creatine monohydrate is the form to use. Not creatine hydrochloride, not creatine ethyl ester, not buffered creatine. Monohydrate has the evidence. The others have the marketing.

There is one clinical consideration that every GLP-1 user on creatine needs to understand: serum creatinine. Creatine is non-enzymatically converted to creatinine in muscle, and creatinine is the biomarker most commonly used to estimate kidney function (GFR). When you supplement creatine, serum creatinine rises — not because your kidneys are failing, but because you have more substrate being converted to the metabolite. Your prescriber sees a creatinine bump on your labs and may panic, especially in a patient they’re already monitoring for potential renal effects of weight loss.

Tell your prescriber before your next blood draw. Show them this if you need to: creatine supplementation raises serum creatinine by approximately 10-20% without any actual change in renal function, as confirmed by cystatin C-based GFR measurement, which is not affected by creatine intake (Gualano et al., 2012, European Journal of Applied Physiology). This is a measurement artifact, not kidney damage. But if you don’t mention it, you may end up with an unnecessary nephrology referral or, worse, have your GLP-1 medication paused over a lab value that doesn’t mean what your prescriber thinks it means.

Creatine monohydrate is available from supplement retailers including leanloss.com, where it’s stocked in the formulations and doses discussed here.

HMB: the anti-catabolic insurance policy

Beta-hydroxy beta-methylbutyrate — HMB — is a metabolite of leucine. Your body produces it naturally in small amounts when you consume leucine-containing protein. Supplemental HMB provides pharmacological doses that exceed what you’d get from diet alone, and its mechanism of action is distinct from leucine itself.

Where leucine activates the anabolic (building) side of the equation via mTORC1, HMB primarily inhibits the catabolic (breakdown) side. Specifically, HMB attenuates the ubiquitin-proteasome proteolysis pathway — the same system that ramps up during caloric restriction to break down muscle proteins for energy (Smith et al., 2005, Journal of Applied Physiology). It also appears to stabilize muscle cell membranes by supporting cholesterol synthesis within myocytes, which may reduce exercise-induced muscle damage (Nissen & Abumrad, 1997, Journal of Nutritional Biochemistry).

The most cited RCT for HMB during caloric restriction is Wilson et al. (2014), published in the Journal of the International Society of Sports Nutrition. In this study, resistance-trained men underwent a highly aggressive caloric deficit while supplementing with either HMB free acid (HMB-FA) or placebo. The HMB group preserved 100% of their lean mass over four weeks. The placebo group lost approximately 1.5 kg of lean mass over the same period. The magnitude of this effect, in a trained population during severe restriction, is notable.

A word of honesty about this evidence: the Wilson study was industry-funded by Metabolic Technologies Inc., which holds patents on HMB-FA. This doesn’t invalidate the findings — industry-funded research is a reality in nutrition science, and the study was peer-reviewed and methodologically sound. But it does mean you should grade the evidence as Moderate-Strong rather than Strong, and interpret the effect size with appropriate caution. Independent replication in a GLP-1-specific population would strengthen the recommendation considerably. That study hasn’t been done yet.

The dose is 3 grams per day, ideally divided into three 1-gram doses taken with meals. The meal timing is not arbitrary. Muscle protein breakdown spikes in the postprandial period when amino acid delivery is low — the exact scenario that GLP-1 users face at nearly every meal. Taking HMB with each meal provides anti-catabolic coverage precisely when the proteolytic drive is highest.

HMB is more expensive than creatine and harder to find in standalone form (it’s often bundled into proprietary blends at sub-therapeutic doses). If budget is a constraint, creatine and protein come first. HMB is the addition you make when the fundamentals are already in place.

Leucine supplementation and enrichment: hitting the threshold every time

We’ve already discussed why the leucine threshold matters — it’s the minimum amount of leucine per meal required to activate mTORC1 and initiate muscle protein synthesis. The question is how to reliably hit it when your appetite has been functionally eliminated by medication.

There are three practical approaches, in order of simplicity.

The first is choosing protein sources with high leucine density. Not all proteins are equal in their leucine content per gram. Whey protein is the richest commonly available source, at roughly 11-13% leucine by weight — meaning a 25-gram serving of whey protein provides approximately 2.8 to 3.3 grams of leucine (Tang et al., 2009, Journal of Applied Physiology). Egg whites are similarly leucine-rich. Chicken breast, Greek yogurt, and cottage cheese are solid whole-food options. If you’re eating any protein during GLP-1 therapy, make it high-leucine protein. Every gram counts more when you’re eating less.

The second approach is adding free-form leucine powder to meals or protein sources that don’t hit the threshold on their own. If you’re eating a plant-based diet, this is particularly relevant. Pea protein, while a reasonable protein source, has lower leucine density than whey — roughly 8% versus 11-13%. A 25-gram serving provides about 2 grams of leucine, which may fall below the activation threshold. Adding 1 to 1.5 grams of free-form leucine to a plant-based protein shake bridges the gap. Leucine powder is inexpensive and unflavored (though it has a mildly bitter taste that blends easily into a shake).

The third approach, already mentioned but worth reiterating: eliminate collagen as a protein source during GLP-1 therapy. Collagen protein is approximately 0.3% leucine. To get 2.5 grams of leucine from collagen alone, you would need to consume over 800 grams of collagen powder. This is obviously impractical. If collagen is a significant fraction of your daily protein intake, you’re hitting your protein number on paper while functionally starving your muscles of the amino acid they need to survive the deficit. Replace collagen with whey, egg, or leucine-enriched plant protein. If you want collagen for its purported skin or joint benefits, treat it as an addition to your protein target, not a component of it.

The leucine threshold concept also explains why meal frequency and distribution matter more during GLP-1 therapy than at any other time. It is better to eat three 35-gram protein meals than two 50-gram protein meals and one 5-gram protein meal — even though total daily intake is lower in the first scenario. Three threshold-crossing events per day versus one or two is a meaningful difference in cumulative MPS stimulation over weeks and months.

The week-by-week protocol

Knowing what works and actually implementing it during GLP-1 therapy are different problems. The appetite suppression, fatigue, and general overwhelm of starting a new medication make it unrealistic to overhaul your exercise and nutrition simultaneously. Here’s a staged approach that prioritizes the highest-impact interventions first and layers additional tools as they become manageable.

Weeks 1 through 2: creatine only. Buy creatine monohydrate. Take 5 grams per day, mixed into water or whatever you’re drinking. That’s it. Don’t change your eating. Don’t start a gym program. Just build the habit of taking creatine daily. This is the lowest-effort, highest-yield intervention you can make, and doing it first — before you’ve exhausted your willpower on bigger changes — means it actually sticks. Your muscles are saturating their phosphocreatine stores while you adjust to the medication.

Weeks 3 through 4: add protein tracking. Download a food tracking app or use a simple notebook. Track your protein intake for two weeks. Don’t try to hit a target yet — just observe. Most GLP-1 users are shocked by how little protein they’re actually eating. Once you see the number, set a minimum target: aim for at least three meals per day that each contain 30 or more grams of protein from high-leucine sources. A protein shake counts as a meal for this purpose. If you can only manage two threshold-crossing meals, that’s still better than zero.

Month 2: resistance training. Start a basic program, two sessions per week. If you have access to a gym: barbell or dumbbell squats, bench press or push-ups, rows, and a hinge movement like Romanian deadlifts. If you’re training at home with minimal equipment: goblet squats with a single dumbbell, push-ups (wall push-ups if floor push-ups are too difficult), dumbbell rows, and glute bridges. Each session should take 30 to 45 minutes. The goal is not to be sore or exhausted — it’s to load your muscles against resistance with progressive overload over time. Add weight or reps every one to two weeks.

Month 2 and beyond (advanced additions): If budget allows and the fundamentals are solid, add HMB — 1 gram three times daily with meals. If protein distribution remains challenging despite your best efforts (you consistently have one or two meals that fall below the leucine threshold), add free-form leucine powder — 2 to 3 grams mixed into those specific meals. These are optimization layers, not foundations. They do not replace resistance training and protein. They enhance them.

Before your next blood draw: Inform your prescriber that you’ve started creatine supplementation. Mention that serum creatinine may be elevated as a normal pharmacokinetic effect, and that cystatin C-based GFR is a more accurate assessment of renal function if there’s any concern. This five-second conversation prevents a potentially disruptive false alarm.

What doesn’t work (clearing the noise)

The supplement and fitness industry is exceptionally good at selling solutions to problems that either don’t exist or that the product doesn’t solve. If you’re a GLP-1 user searching for muscle preservation advice, you will encounter a wall of recommendations that sound reasonable but fail on mechanism. Here are the most common ones, and why they don’t do what you need.

Collagen peptides have already been discussed, but they deserve emphasis here because the marketing is so effective. Collagen is positioned as a protein supplement, and it technically is one — it contains amino acids. But its amino acid profile is dominated by glycine, proline, and hydroxyproline, which are essentially irrelevant to muscle protein synthesis. Collagen does not meaningfully activate mTORC1. Consuming 20 grams of collagen protein instead of 20 grams of whey protein means you miss a leucine threshold crossing that would have triggered MPS. Over months, these missed opportunities compound into measurably more muscle loss. Collagen may have benefits for connective tissue, but it is not a muscle-preserving protein, and marketing it as such to a vulnerable population is borderline irresponsible.

BCAAs (branched-chain amino acids) as a standalone supplement are unnecessary if your total protein intake is adequate and leucine-rich. BCAAs contain leucine, isoleucine, and valine. The leucine component is what matters for MPS. But if you’re already consuming 1.6 to 2.2 grams per kilogram of protein from whole food and whey sources, you’re getting more than enough leucine within your meals. Adding BCAAs on top of adequate protein doesn’t further stimulate MPS — you’ve already crossed the threshold. BCAAs are only potentially useful if your total protein intake is very low and you cannot increase it, which is a scenario better solved by drinking a protein shake than by taking a BCAA capsule (Wolfe, 2017, Journal of the International Society of Sports Nutrition).

High-repetition, low-weight “toning” routines are pervasive in fitness content aimed at women and older adults, and they are insufficient for muscle preservation during a significant caloric deficit. The mechanical stimulus required to trigger muscle-preserving adaptations requires sufficient load — a weight that you can lift for 6 to 30 repetitions but that challenges you near the end of the set (Schoenfeld et al., 2017, Journal of Strength and Conditioning Research). If you’re doing sets of 50 with two-pound dumbbells, the load is below the threshold for meaningful mechanotransduction signaling. You are burning calories and improving muscular endurance, but you are not providing the stimulus your muscles need to resist catabolism during severe energy restriction. Use a weight that makes the last two to three reps of each set genuinely difficult. That’s the signal.

Fasted cardio — performing cardiovascular exercise in the morning before eating — is often recommended for fat loss on the theory that low glycogen stores force the body to oxidize fat. The reality during GLP-1 therapy is more problematic. Fasted exercise in an already-depleted individual increases muscle protein breakdown acutely (Tipton et al., 2001, American Journal of Physiology). Cortisol is elevated during fasted exercise, which promotes proteolysis. Amino acid availability is at its lowest point after an overnight fast. If your goal is muscle preservation, performing intense exercise in the most catabolic state of your day is counterproductive. Eat something with protein before training, even if it’s small — 20 grams of whey protein in water is enough to shift the amino acid environment away from net breakdown.

Honest caveats and what we don’t know

This article draws heavily on caloric restriction research, resistance training literature, and supplement trials that were not conducted specifically in GLP-1 user populations. The physiological principles transfer — a caloric deficit is a caloric deficit regardless of whether it was drug-induced or behavior-driven — but the specific population dynamics of GLP-1 users (appetite profiles, medication interactions, comorbidity patterns, age distribution) may modify the effect sizes in ways we haven’t measured yet.

The GLP-1-specific muscle preservation literature is in its infancy. There are a handful of small trials examining body composition outcomes with exercise during semaglutide therapy, and they broadly confirm that resistance training helps (Lundgren et al., 2024, JAMA Network Open). But we don’t have large, long-term RCTs examining the combined effect of resistance training plus creatine plus protein optimization in GLP-1 users versus GLP-1 alone. That trial needs to happen. Until it does, we’re extrapolating from adjacent bodies of evidence, which is common in clinical practice but worth acknowledging.

Individual responses to resistance training vary meaningfully based on age, sex, training history, hormonal status, and genetics. A 35-year-old man with prior gym experience will preserve muscle more easily than a 68-year-old woman who has never resistance trained. Both will benefit from the interventions described here, but the magnitude of benefit will differ, and the older, untrained individual may need closer supervision and more gradual progression.

If you have chronic kidney disease, the protein targets discussed in this article (1.6 to 2.2 grams per kilogram) may be inappropriate for you. High protein intake increases renal workload, and in patients with already-compromised kidney function, this can accelerate decline. Talk to your prescriber or nephrologist before substantially increasing protein intake. This is one area where individualized medical guidance is not optional — it’s essential. Similarly, creatine supplementation in patients with known kidney disease warrants a conversation with a physician, even though the evidence in healthy populations shows no renal risk at standard doses (Kreider et al., 2017, Journal of the International Society of Sports Nutrition).

The long-term skeletal effects of rapid weight loss on GLP-1 therapy are another area of genuine uncertainty. DXA scans measure lean mass, which includes bone mineral content. Some portion of the “lean mass loss” reported in trials may reflect declining bone density rather than muscle loss specifically. Early data suggests that bone mineral density does decrease during GLP-1 therapy (Blau et al., 2024, The Journal of Clinical Endocrinology & Metabolism), but whether this translates to increased fracture risk over decades is unknown. Resistance training and adequate protein intake support both muscle and bone, so the interventions overlap, but this is a space where we need more data and where your prescriber should be involved in monitoring.

The hierarchy, and where to start

The evidence supports a clear ordering of priorities for muscle preservation during GLP-1 therapy.

Resistance training is first. It is the only intervention that directly stimulates the molecular pathways responsible for muscle maintenance during caloric restriction. Nothing substitutes for it. Two sessions per week of compound exercises with progressive overload is the minimum effective dose.

Protein optimization is second. Target 1.6 to 2.2 grams per kilogram of body weight per day, distributed across at least three meals that each cross the leucine threshold of 2.5 to 3 grams. Choose high-leucine protein sources. Track intake during the first month until you know your patterns. A whey protein shake is the simplest tool to hit the threshold when appetite is low.

Creatine monohydrate is third but is the easiest to start. Three to five grams per day, every day. Strong evidence for lean mass preservation during resistance training and caloric restriction. Minimal side effects. Inform your prescriber about the serum creatinine artifact.

HMB is fourth. Three grams per day in divided doses with meals. Moderate-strong evidence for anti-catabolic effects during severe restriction. More expensive and harder to source than creatine. Add it once the first three interventions are established.

Leucine enrichment is fifth. Free-form leucine added to meals that don’t cross the threshold on their own. Most relevant for plant-based eaters or those who struggle with protein distribution despite tracking.

Don’t try to implement all of these on day one. You’re already adjusting to a medication that has fundamentally altered your relationship with food. Start with creatine because it requires no behavior change — just a scoop of powder in water. Add protein awareness in weeks three and four. Start resistance training in month two. Layer HMB and leucine enrichment later if needed. Each step reduces the proportion of muscle in your total weight loss. The first two steps — resistance training and protein — do the majority of the work. The supplements optimize the margins.

Your prescriber may not bring this up. The clinical framework for GLP-1 therapy is still oriented around total weight loss as the outcome that matters. But your body composition — how much of that weight loss is fat versus muscle — is what determines whether you end up healthier or just lighter. You now have the information to make it the former. Use it.